Beam Therapeutics (BEAM) Status Update summary

Strategic Vision and Technology Platform

• Focus on developing lifelong, one-time curative therapies for serious genetic diseases using precision base editing, targeting both rare and common disorders.

• Base editing enables precise, predictable single-base changes without double-stranded DNA breaks, improving safety and control over traditional CRISPR methods and allowing gene correction, silencing, activation, and multiplex editing.

• The platform supports rapid creation of new therapies, with validated clinical translation, in vivo and ex vivo delivery, GMP manufacturing, and potential for expansion into more common diseases.

• Beam is advancing a diversified portfolio of base editing programs, focusing on life-long cures for serious diseases.

• Strategic partnerships with Pfizer, Apellis, Lilly, and Sana have generated $675M upfront and over $1B in potential milestones, expanding the reach and impact of Beam's technology.

Pipeline and Clinical Progress

• The pipeline includes BEAM-101 for sickle cell disease, BEAM-302 for alpha-1 antitrypsin deficiency, BEAM-301 for glycogen storage disease 1a, and BEAM-201 for T-cell malignancies.

• BEAM-101 shows best-in-class potential for SCD, with BEACON Phase 1/2 trial demonstrating rapid enrollment, adolescent inclusion, and promising early data.

• BEAM-302 and BEAM-301 have received regulatory clearances, with initial patient dosing and data readouts anticipated in 2025.

• BEAM-301 aims to restore glucose homeostasis in GSD1a; preclinical studies showed improved survival, and Phase 1/2 trial is set to begin dosing in early 2025.

• BEAM-201 targets T-cell malignancies, expanding the therapeutic pipeline.

BEAM-101 BEACON Study Results

• In the BEACON phase I/II trial, 11 patients have been dosed, showing rapid neutrophil and platelet engraftment, low neutropenic days, and no post-engraftment vaso-occlusive events.

• All patients achieved robust and sustained increases in total hemoglobin and HbF (>60%), with corresponding reduction in HbS (<40%) and normalization of hemolysis markers.

• High editing rates in peripheral blood confirmed successful engraftment and persistence of gene-edited cells.

• Safety profile consistent with busulfan conditioning; one unrelated death occurred, attributed to busulfan toxicity, not BEAM-101.

• Treated patients showed near-complete elimination of sickled cells, improved deformability, reduced adhesion, and normalized hemolysis markers.